Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the
oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and …

Background The therapeutic potency of Rigosertib (RGS) in the treatment of the
myelodysplastic syndrome has been investigated previously, but little is known about its …

Approximately 45% of colorectal cancers harbor mutations in the KRAS gene, resulting in
constitutive activation of RAS signaling through effector proteins, primarily RAF and PI3K …

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

KRAS mutations are common driver oncogenes associated with the development of several
solid tumors. KRAS oncogene has been considered a highly challenging target for drug …

Colorectal cancer (CRC) is among the most commonly diagnosed cancers affecting both
genders in the world. It is characterized by genetic instability, which drives tumor formation …

The V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently
dysregulated in colorectal cancer (CRC). It is involved in the modulation of several …

The RAS gene family, responsible for signal transduction within the mitogen activated
protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K) pathways, is frequently …

With the advent of Kirsten rat sarcoma viral oncogene homologue G12C (KRAS G12C)
inhibitors, RAS is no longer considered undruggable. For the suppression of RAS, new …

KRAS is a gatekeeper gene in human colorectal tumorigenesis. KRAS is 'undruggable';
hence, efforts have been diverted to inhibit downstream RAF/MEK/ERK and PI3K/Akt …